Skip to main content
. Author manuscript; available in PMC: 2020 Dec 12.
Published in final edited form as: Clin Nucl Med. 2017 Jun;42(6):436–443. doi: 10.1097/RLU.0000000000001629

TABLE 3:

RECIST Criteria Evaluation for All Patients

Organ Number of cases
(%)		 PD
(%)		 SD
(%)		 PR
(%)		 CR
(%)		 Not Evaluable
(%)
MID-GUT 59
(41.2%)		 19
(32.2%)		 32
(50.1%)		 2
(6.8%)		 --- 6
(10.2%)
PANCREAS 48
(33.53%)		 23
(47.9%)		 18
(37.5%)		 6
(12.5%)		 --- 1
(2.08%)
PULMONARY 14
(9.8%)		 5
(37.5%)		 6
(42.9%)		 2
(14.2%)		 --- 1
(7.1%)
THYMUS 2
(1.4%)		 2
(100%)		 --- --- --- ---
PROSTATE 1
(0.7%)		 --- --- --- --- 1
(100%)
PHEOCROMOCYTOMA 1
(0.7%)		 --- 1
(100%)		 --- --- ---
PARAGANGLIOMA 4
(2.8%)		 1
(25%)		 3
(75%)		 --- --- ---
NEUROBLASTOMA 1
(0.7%)		 1
(100%)		 --- --- --- ---
OVARY 1
(0.7%)		 --- --- 1
(100%)		 --- ---
MERCKEL CELL 2
(1.4%)		 1
(50%)		 --- --- --- 1
(50%)
UNKNOWN 10
(7%)		 2
(20%)		 6
(60%)		 1
(10%)		 --- 1
(10%)
TOTAL 143 54 (37.7%) 66 (46.1%) 12 (8.39%) 0 (0%) 11 (7%)